At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 354 enrolled
Drug / intervention
Obicetrapib +1 moredrug
Likely dose
Obicetrapib 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies
In Brief
A Phase 3 clinical trial evaluating Obicetrapib and Placebo for Dyslipidemias and 8 related conditions. Completed, enrolled 354 participants across 96 sites in 10 countries.
Detailed Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia (HeFH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
CountriesCanada, Czechia, Georgia, Netherlands, Norway, Poland, South Africa, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartJul 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedJun 21, 2022
Enrollment StartJul 25, 2022
Primary CompletionMay 28, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.0 years ago
Interventions
Obicetrapibdrug
10 mg Obicetrapib tablet
Placebodrug
placebo tablet made to resemble active